Literature DB >> 17876718

Effect of 'attenuated' mutations in mucopolysaccharidosis IVA on molecular phenotypes of N-acetylgalactosamine-6-sulfate sulfatase.

A M Montaño1, K Sukegawa, Z Kato, R Carrozzo, P Di Natale, E Christensen, K O Orii, T Orii, N Kondo, S Tomatsu.   

Abstract

Mucopolysaccharidosis IVA is an autosomal recessive disease caused by the deficiency of N-acetylgalactosamine-6-sulfate sulfatase (GALNS). Mutation screening of the GALNS gene was performed for seven MPS IVA patients with attenuated phenotypes from three unrelated families. Four of 5 missense mutations identified in this study (p.F167V, p.R253W, p.R380S, p.P484S) and two reported (p.F97V, p.N204K), associated with attenuated phenotypes, were characterized using in vitro stable expression experiments, enzyme kinetic study, protein processing and structural analysis. The stably expressed mutant enzymes defining the attenuated phenotype exhibited a considerable residual activity (1.2-36.7% of the wild-type GALNS activity) except for p.R380S. Enzyme kinetic studies showed that p.F97V, p.F167V and p.N204K have lower affinity to the substrate compared with other mutants. The p.F97V enzyme was the most thermolabile at 55 degrees C. Immunoblot analyses indicated a rapid degradation and/or an insufficiency in processing in the mutant proteins. Tertiary structure analysis revealed that although there was a tendency for 'attenuated' mutant residues to be located on the surface of GALNS, they have a different effect on the protein including modification of the hydrophobic core and salt-bridge formation and different potential energy. This study demonstrates that 'attenuated' mutant enzymes are heterogeneous in molecular phenotypes, including biochemical properties and tertiary structure.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17876718     DOI: 10.1007/s10545-007-0702-z

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  37 in total

1.  Mucopolysaccharidosis IVA: four new exonic mutations in patients with N-acetylgalactosamine-6-sulfate sulfatase deficiency.

Authors:  S Tomatsu; S Fukuda; A Yamagishi; A Cooper; J F Wraith; T Hori; Z Kato; N Yamada; K Isogai; K Sukegawa; N Kondo; Y Suzuki; N Shimozawa; T Orii
Journal:  Am J Hum Genet       Date:  1996-05       Impact factor: 11.025

2.  Structure of a human lysosomal sulfatase.

Authors:  C S Bond; P R Clements; S J Ashby; C A Collyer; S J Harrop; J J Hopwood; J M Guss
Journal:  Structure       Date:  1997-02-15       Impact factor: 5.006

3.  Efficient selection for high-expression transfectants with a novel eukaryotic vector.

Authors:  H Niwa; K Yamamura; J Miyazaki
Journal:  Gene       Date:  1991-12-15       Impact factor: 3.688

4.  Mucopolysaccharidosis IVA: a novel splice acceptor site mutation in intron 4 of the N-acetylgalactosamine-6-sulfate sulfatase gene in an Afghanistan girl with classical Morquio disease.

Authors:  S Fukuda; N Yamada; S Tomatsu; K Sukegawa; A M Montaño; J J Hopwood; V Muller; T Orii; N Kondo
Journal:  Jpn J Hum Genet       Date:  1997-06

5.  Residual activity in fibroblasts from two brothers with the late-onset form of N-acetylgalactosamine-6-sulphate sulphatase deficiency.

Authors:  K Sukegawa; T Orii
Journal:  J Inherit Metab Dis       Date:  1982       Impact factor: 4.982

6.  Effect of Hunter disease (mucopolysaccharidosis type II) mutations on molecular phenotypes of iduronate-2-sulfatase: enzymatic activity, protein processing and structural analysis.

Authors:  K Sukegawa-Hayasaka; Z Kato; H Nakamura; S Tomatsu; T Fukao; K Kuwata; T Orii; N Kondo
Journal:  J Inherit Metab Dis       Date:  2006-11-07       Impact factor: 4.982

7.  Mucopolysaccharidosis IVA (Morquio A): identification of novel common mutations in the N-acetylgalactosamine-6-sulfate sulfatase (GALNS) gene in Italian patients.

Authors:  Shunji Tomatsu; Mirella Filocamo; Koji O Orii; William S Sly; Monica A Gutierrez; Tatsuo Nishioka; Olga Peña Serrato; Paola Di Natale; Adriana Maria Montaño; Seiji Yamaguchi; Naomi Kondo; Tadao Orii; Akihiko Noguchi
Journal:  Hum Mutat       Date:  2004-08       Impact factor: 4.878

8.  Mucopolysaccharidosis type IVA. N-acetylgalactosamine-6-sulfate sulfatase exonic point mutations in classical Morquio and mild cases.

Authors:  S Fukuda; S Tomatsu; M Masue; K Sukegawa; H Iwata; T Ogawa; Y Nakashima; T Hori; A Yamagishi; Y Hanyu
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

9.  N-acetylgalactosamine-6-sulfate sulfatase in human placenta: purification and characteristics.

Authors:  M Masue; K Sukegawa; T Orii; T Hashimoto
Journal:  J Biochem       Date:  1991-12       Impact factor: 3.387

10.  Mucopolysaccharidosis IVA: screening and identification of mutations of the N-acetylgalactosamine-6-sulfate sulfatase gene.

Authors:  T Ogawa; S Tomatsu; S Fukuda; A Yamagishi; G M Rezvi; K Sukegawa; N Kondo; Y Suzuki; N Shimozawa; T Orü
Journal:  Hum Mol Genet       Date:  1995-03       Impact factor: 6.150

View more
  14 in total

1.  Molecular characterization of 355 mucopolysaccharidosis patients reveals 104 novel mutations.

Authors:  Laura M Pollard; Julie R Jones; Tim C Wood
Journal:  J Inherit Metab Dis       Date:  2012-09-14       Impact factor: 4.982

2.  Enzyme replacement therapy for Morquio A: an active recombinant N-acetylgalactosamine-6-sulfate sulfatase produced in Escherichia coli BL21.

Authors:  Alexander Rodríguez; Angela J Espejo; Alejandra Hernández; Olga L Velásquez; Lina M Lizaraso; Henry A Cordoba; Oscar F Sánchez; Carlos J Alméciga-Díaz; Luis A Barrera
Journal:  J Ind Microbiol Biotechnol       Date:  2010-06-27       Impact factor: 3.346

3.  Non-invasive pulmonary function test on Morquio patients.

Authors:  Francyne Kubaski; Shunji Tomatsu; Pravin Patel; Tsutomu Shimada; Li Xie; Eriko Yasuda; Robert Mason; William G Mackenzie; Mary Theroux; Michael B Bober; Helen M Oldham; Tadao Orii; Thomas H Shaffer
Journal:  Mol Genet Metab       Date:  2015-06-23       Impact factor: 4.797

4.  Mucopolysaccharidosis IVA: correlation between genotype, phenotype and keratan sulfate levels.

Authors:  Vũ Chí Dũng; Shunji Tomatsu; Adriana M Montaño; Gary Gottesman; Michael B Bober; William Mackenzie; Miho Maeda; Grant A Mitchell; Yasuyuki Suzuki; Tadao Orii
Journal:  Mol Genet Metab       Date:  2013-06-26       Impact factor: 4.797

5.  Molecular testing of 163 patients with Morquio A (Mucopolysaccharidosis IVA) identifies 39 novel GALNS mutations.

Authors:  A Morrone; K L Tylee; M Al-Sayed; A C Brusius-Facchin; A Caciotti; H J Church; M J Coll; K Davidson; M J Fietz; L Gort; M Hegde; F Kubaski; L Lacerda; F Laranjeira; S Leistner-Segal; S Mooney; S Pajares; L Pollard; I Ribeiro; R Y Wang; N Miller
Journal:  Mol Genet Metab       Date:  2014-03-20       Impact factor: 4.797

6.  Computational analysis of human N-acetylgalactosamine-6-sulfate sulfatase enzyme: an update in genotype-phenotype correlation for Morquio A.

Authors:  Sergio Olarte-Avellaneda; Alexander Rodríguez-López; Carlos Javier Alméciga-Díaz; Luis Alejandro Barrera
Journal:  Mol Biol Rep       Date:  2014-10-07       Impact factor: 2.316

Review 7.  Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA.

Authors:  C J Hendriksz; P Harmatz; M Beck; S Jones; T Wood; R Lachman; C G Gravance; T Orii; S Tomatsu
Journal:  Mol Genet Metab       Date:  2013-04-10       Impact factor: 4.797

8.  Umbilical mesenchymal stem cell-derived extracellular vesicles as enzyme delivery vehicle to treat Morquio A fibroblasts.

Authors:  Michael Flanagan; Isha Pathak; Qi Gan; Linda Winter; Ryan Emnet; Salem Akel; Adriana M Montaño
Journal:  Stem Cell Res Ther       Date:  2021-05-06       Impact factor: 6.832

9.  Bisphosphonate Treatment in a Patient Affected by MPS IVA with Osteoporotic Phenotype.

Authors:  Albina Tummolo; Orazio Gabrielli; Alberto Gaeta; Maristella Masciopinto; Lucia Zampini; Luigi Michele Pavone; Paola Di Natale; Francesco Papadia
Journal:  Case Rep Med       Date:  2013-11-18

10.  Molecular analysis in a GALNS study cohort of 15 Tunisian patients: description of a novel mutation.

Authors:  Latifa Chkioua; Souhir Khedhiri; Hind Hafsi; Oussama Grissa; Hadhami Ben Turkia; Abdelhedi Miled; Sandrine Laradi; Roseline Froissart; Najat Alif
Journal:  Diagn Pathol       Date:  2016-06-17       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.